| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Urotensin-2 receptor, UR-2-R, G-protein coupled receptor 14, Urotensin II receptor, UR-II-R, UTS2R, GPR14 |
| Entrez GeneID | 2837 |
| WB Predicted band size | 42.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This UTS2R antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 223-252 amino acids from the Central region of human UTS2R. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与UTS2R(Urotensin II受体)抗体相关的代表性文献(内容为模拟示例)：
1. **文献名称**: "Development of a specific monoclonal antibody for human urotensin II receptor detection"
**作者**: Smith A, et al.
**摘要**: 本研究成功开发了一种针对人UTS2R胞外结构域的高特异性单克隆抗体。通过免疫印迹和免疫组化验证，该抗体能有效识别多种组织(如心脏、血管内皮)中的UTS2R蛋白表达，为研究其在心血管疾病中的作用提供了工具。
2. **文献名称**: "Urotensin II receptor expression in hepatocellular carcinoma: A novel prognostic biomarker"
**作者**: Chen L, et al.
**摘要**: 通过使用抗UTS2R多克隆抗体进行免疫组化分析，发现肝癌组织中UTS2R的过表达与患者生存率降低显著相关，提示该受体可能成为肝癌治疗的新靶点。
3. **文献名称**: "Characterization of UT receptor antibodies for functional studies in rodent models"
**作者**: Tanaka K, et al.
**摘要**: 本研究系统比较了多种商业抗UTS2R抗体的特异性，发现部分抗体存在交叉反应性。通过基因敲除模型验证后，筛选出适用于大鼠脑组织免疫荧光染色和流式细胞术的高效抗体。
注：以上文献为示例性质，实际引用时需根据具体研究领域核实真实存在的文献。UTS2R相关研究多集中于心血管生理、肿瘤及代谢疾病领域，抗体开发类文献相对较少，部分研究可能使用受体拮抗剂而非抗体。建议通过PubMed等数据库以"Urotensin II receptor antibody"为关键词检索最新进展。
The urotensin II receptor (UTS2R), also known as GPR14. is a class A G protein-coupled receptor (GPCR) that binds urotensin II (UII), a cyclic peptide involved in diverse physiological processes. First identified in the early 2000s, UTS2R is expressed in cardiovascular tissues, the central nervous system, kidneys, and endocrine organs. It activates multiple signaling pathways, including Gαq/11-mediated phospholipase C activation and subsequent calcium mobilization, regulating vascular tone, cell proliferation, and inflammation. Dysregulation of the UII-UTS2R system has been linked to cardiovascular diseases (e.g., hypertension, atherosclerosis), metabolic disorders, and cancer, making it a potential therapeutic target.
UTS2R antibodies are critical tools for studying receptor localization, expression levels, and functional mechanisms in both normal and pathological states. Polyclonal and monoclonal antibodies targeting specific epitopes (e.g., extracellular loops or intracellular domains) enable techniques like immunohistochemistry, Western blotting, and flow cytometry. Some antibodies also serve as antagonists to block UII-induced signaling, aiding in drug discovery. Challenges include ensuring specificity due to structural similarities among GPCRs. Recent research focuses on developing therapeutic antibodies to modulate UTS2R activity, offering promise for treating conditions like heart failure or diabetic nephropathy. However, clinical applications remain exploratory, necessitating further validation of antibody efficacy and safety.
×
